Maximizing therapeutic gain with gemcitabine and fractionated radiation

International Journal of Radiation Oncology Biology Physics

Volumn 44, Issue 5, 1999, Pages 1125-1135

  Mason, Kathy A ^a   Milas, Luka ^a   Hunter, Nancy R ^a   Elshaikh, Mohamed ^a   Buchmiller, Lara ^a   Kishi, Kazushi ^a   Hittelman, K Walter ^b   Ang, K Kian ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Dept of Clinical Investigations ^*  (United States)

Author keywords

Fractionated irradiation; Gemcitabine; Jejunum; SA NH tumor; Therapeutic gain

Indexed keywords

CESIUM 137; GEMCITABINE;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CELL SURVIVAL; CONTROLLED STUDY; GAMMA IRRADIATION; INTESTINE CRYPT; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; JEJUNUM MUCOSA; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PROTECTION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; INTESTINAL MUCOSA; JEJUNUM; MICE; MICE, INBRED C3H; RADIATION-SENSITIZING AGENTS; SARCOMA, EXPERIMENTAL; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 0032815755     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00134-0     Document Type: Article

References (48)

1. Milas L., Fuji T., Hunter N., et al. Ehancement of tumor radioresponse in vivo by gemcitabine. Cancer Res. 59:1999;107-114.
2. Elshaikh M, Hunter N, Milas L; et al. Time dependent modulation of jejunal radioresponse with gemcitabine. (Abstr.) Proceedings of the 45th Annual Meeting of the Radiation Research Society, Providence, RI, 1997. p. 228.
3. Vokes E.E., Weichselgaum R., Lippman S.M., et al. Head and neck cancer. N Engl J Med. 328:1993;184-194.
4. Taylor S.G., Murthy A.K., Vannetzel J.-M., et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol. 12:1994;385-395.
5. El-Sayed S., Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: A meta-analysis of prospective and randomized trials. J Clin Oncol. 14:1996;838-847.
6. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 324:1991;1685-1690.
7. Herskovic A., Martz K., Al-Sarraf M., et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 326:1992;1593-1598.
8. Pignon J.-P., Arriagada R., Ihde D.C., et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 327:1992;1618-1624.
9. Milas L., Hunter N.R., Mason K.A., et al. Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res. 54:1994;3506-3510.
10. Milas L., Milas M.M., Mason K.A. Combination of taxanes with radiation Preclinical studies . Semin Radiat Oncol. 9:1999;12-26.
11. Gregoire V., Hittelman W.N. Nucleoside analogs in cancer therapy. Vol. 12:1997;Marcel Dekker, Inc, New York.
12. McGinn C.J., Shewach D.S., Lawrence T.S. Review Radiosensitizing nucleosides . J Natl Cancer Inst. 88:1996;1193-1203.
13. Catapano C.V., Perrino F.W., Fernandes D.J. Primer RNA chain termination induced by 9-b-D-arabinofuranosyl-2-fluoradenine 5′triphosphate. J Biol Chem. 268:1993;7179-7185.
14. Huang NJ, Hittelman WN. Transient inhibition of chromosome damage repair after ionizing radiation by gemcitabine. (Abstr.) American Association of Cancer Research: 1995. p. A3643.
15. Tseng W.C., Derse D., Cheng Y.C., et al. In vitro biological activity of 9-b-D-arabinofuranosyl-2-fluoroadenosine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol Pharmacol. 21:1982;474-477.
16. Yang S.W., Huang P., Plunkett W., et al. Dual mode of inhibition of purified DNA ligase I from human cells by 9-b-D-arabinofuranosyl-2-fluoroadenosine. J Biol Chem. 267:1992;2345-2349.
17. Gregoire V., Hunter N., Brock W.A., et al. Fludarabine improves the therapeutic ratio of radiotherapy in mouse tumors after single dose irradiation. Int J Radiat Oncol Biol Phys. 30:1994;363-371.
18. Gregoire V., Hunter N., Milas L., et al. Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine. Cancer Res. 54:1994;468-474.
19. Gregoire V., Hunter N.R., Brock W.A., et al. Improvement in therapeutic ratio of radiotherapy for a murine sarcoma by indomethacin plus fludarabine. Radiat Res. 146:1996;548-553.
20. Gregoire V., Ruifrok A.C.C., Price R.E., et al. Effect of intra-peritoneal fludarabine administration on rat spinal cord tolerance to fractionated irradiations. Radiother Oncol. 36:1995;50-55.
21. Gregoire V., Van N.T., Stephens L.C., et al. The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo. Cancer Res. 54:1994;6201-6209.
22. Heinemann V., Hertel L.W., Grindey G.B., et al. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-b-D-arabinofurano-sylcytosine. Cancer Res. 48:1988;4014-4031.
23. Hanauske A.-R., Von Hoff D.D. Clinical development of fludarabine. Cheson B.D., Keating M.J., Plunkett W. Nucleoside analogs in cancer therapy. 1997;113-158 Marcel Dekker, Inc, New York.
24. Hertel L.W., Boder G.B., Kroin J.S., et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res. 50:1990;4417-4422.
25. Braakhuis B.J., van Dongen G.A., Vermorken J.B., et al. Preclinical in vivo activity of 2′,2′-difluorodeoxyctidine (gemcitabine) against human head and neck cancer. Cancer Res. 51:1991;211-214.
26. Braakhuis B.J.M., Ruiz van Haperen V.W.T., Welters M.J.P., et al. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer. 31A:1995;2335-2340.
27. Guchelaar H.J., Richel D.J., van Knapen A. Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer Treat Rev. 22:1996;15-31.
28. Hertel L.W., Kroin J.S., Misner J.W., et al. Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2-difluoro-D-ribofuranosyl nycleotides. J Org Chem. 53:1988;2406-2409.
29. Plunkett W., Gandhi V., Chubb S., et al. 2′,2′-difluoro-deoxycytidine metabolism and mechanism of action in human leukaemia cells. Nucleosides Nucleotides. 8:1989;775-785.
30. Plunkett W., Huang P., Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs. 6:1995;7-13.
31. Rockwell S., Grindey G.B. Effect of 2′,2′-difluorodeoxycytieine on the viability and radiosensitivity of EMT6 cells in vitro. Oncol Res. 4:1992;4151-4155.
32. Shewach D.S., Hahn T.M., Chang E., et al. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res. 54:1994;3218-3223.
33. Lawrence T.S., Chang E.Y., Hahn T.M., et al. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoroo-2′-deoxycytidine. Int J Radiat Oncol Biol Phys. 34:1996;867-872.
34. Latz D., Fleckenstein K., Eble M., et al. Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys. 41:1998;875-882.
35. Gregoire V., Beauduin M., Bruniaux M., et al. Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresis. Int J Radiat Biol. 73:1998;511-520.
36. Joschko M.A., Webster L.K., Groves J., et al. Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model. Radiat Oncol Invest. 5:1997;62-71.
37. Milas L., Hunter N., Mason K.A., et al. Immunological resistance to pulmonary metastases in C3Hf/Bu mice bearing syngeneic fibrosarcoma of different sizes. Cancer Res. 34:1974;61-71.
38. Withers H.R., Elkind M.M. Microcolony survival assay for cells of mouse intestinal mucosa exposed to radiation. Int J Radiat Biol. 17:1970;261-267.
39. Stephens L.C., Ang K.K., Schultheiss T.E., et al. Apoptosis in irradiated murine tumor. Radiat Res. 127:1991;308.
40. Meyn R.E., Stephens L.C., Hunter N.R., et al. Apoptosis in murine tumors treated with chemotherapy agents. Anticancer Drugs. 66:1995;443-450.
41. Milas L., Hunter N.R., Kurdoglu B., et al. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother Pharmacol. 35:1995;297-303.
42. Mason K.A., Milas L., Peters L.J. Effect of paclitaxel (Taxol) alone and in combination with radiation on the gastrointestinal mucosa. Int J Radiat Oncol Biol Phys. 32:1995;1381-1389.
43. Weil M.M., Stephens L.C., Amos C.I., et al. Strain difference in jejunal crypt cell susceptibility to radiation-induced apoptosis. Int J Radiat Biol. 70:1996;579-585.
44. Ruifrok A.C.C., Mason K.A., Thames H.D. Changes in clonogen number and radiation sensitivity in mouse jejunal crypts after treatment with dimethylsulfoxide and retinoic acid. Radiat Res. 145:1996;740-745.
45. Ruifrok A.C., Mason K.A., Lozano G., et al. Spatial and temporal patterns of expression of epidermal growth factor, transforming growth factor alpha and transforming growth factor beta 1-3 and their receptors in mouse jejunum after radiation treatment. Radiat Res. 147:1997;1-12.
46. Lawrence T.S., Eisbruch A., Shewach D.S. Gemcitabine-mediated radiosensitization. Semin Oncol. 24:(Suppl. 7):1997;24-28.
47. Vokes E.E., Gregor A., Turrisi A.T. Gemcitabine and radiation therapy for non-small cell lung cancer. Semin Oncol. 25:1998;66-69.
48. Gregoire V., Beauduin M., Rosier J.-F., et al. Kinetics of mouse jejunum radiosensitization by 2′,2′-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells. Br J Cancer. 76:1997;1315-1321.